RNA甲基化在肺癌中的研究进展

doi:10.11904/j.issn.1002-3070.2024.06.011

Abstract

Abstract: Lung cancer is one of the most common cancers.Although there has been a significant improvement in our understanding the risk,development,immune control,and treatment options of lung cancer,the limited understanding of its pathogenesis has resulted in insufficient targeted treatment strategies.In recent years,RNA methylation has become a research hot topic in the field of epigenetics,and proteins regulating RNA methylation have become important targets for cancer treatment.At present,some studies have reported the relationship between RNA methylation and biological processes such as oncogene expression,glycolysis,and immune response in lung cancer,but there is still no in-depth research and analysis.This article will start with the relationship between RNA methylation and lung cancer,explore the association between RNA methylation and the pathogenesis of lung cancer based on existing research,and discuss its future development direction.

Key words: Lung cancer, M6A methylation, N7-methylguanosine, 5-methylcytosine, N1-methyladenosine

CLC Number:

R734.2

CHEN Xingyan, LI Xue, FU Qiang. Research progress of RNA methylation in lung cancer[J]. Journal of Practical Oncology, 2024, 38(6): 421-426.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2024.06.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2024/V38/I6/421

References

1 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
2 Wang LF,Wu LP,Wen JD.LncRNA AC079630.4 expression associated with the progression and prognosis in lung cancer[J].Aging(Albany NY),2021,13(14):18658-18668.
3 Teng PC,Liang Y,Yarmishyn AA,et al.RNA modifications and epigenetics in modulation of lung cancer and pulmonary diseases[J].Int J Mol Sci,2021,22:10592.
4 Schaefer M,Kapoor U,Jantsch MF.Understanding RNA modifications:the promises and technological bottlenecks of the ′epitranscriptome′[J].Open Biol,2017,7(5):170077.
5 Gu C,Shi X,Dai C,et al.RNA m6A Modification in cancers:Molecular mechanisms and potential clinical applications[J].Innovation(Camb),2020,1(3):100066.
6 Deng LJ,Deng WQ,Fan SR,et al.m6A modification:recent advances,anticancer targeted drug discovery and beyond[J].Mol Cancer,2022,21(1):52.
7 Li Y,Su R,Deng X,et al.FTO in cancer:functions,molecular mechanisms,and therapeutic implications[J].Trends Cancer,2022,8(7):598-614.
8 Qu J,Yan H,Hou Y,et al.RNA demethylase ALKBH5 in cancer:from mechanisms to therapeutic potential[J].J Hematol Oncol,2022,15(1):8.
9 Shi H,Wei J,He C.Where,when,and how:context-dependent functions of RNA methylation writers,readers,and erasers[J].Mol Cell,2019,74(4):640-650.
10 Sheng Y,Wei J,Yu F,et al.A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex-mediated DNA replication[J].Blood,2021,138(26):2838-2852.
11 Li B,Zhu L,Lu C,et al.circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity[J].Nat Commun,2021,12(1):295.
12 Yin H,Chen L,Piao S,et al.M6A RNA methylation-mediated RMRP stability renders proliferation and progression of non-small cell lung cancer through regulating TGFBR1/SMAD2/SMAD3 pathway[J].Cell Death Differ,2023,30(3):605-617.
13 Hu Z,Zhu L,Zhang Y,et al.N6-methyladenosine-induced SVIL antisense RNA 1 restrains lung adenocarcinoma cell proliferation by destabilizing E2F1[J].Bioengineered,2022,13:3093-3107.
14 Ning J,Wang F,Bu J,et al.Down-regulated m6A reader FTO destabilizes PHF1 that triggers enhanced stemness capacity and tumor progression in lung adenocarcinoma[J].Cell Death Discov,2022,8(1):354.
15 Liu XS,Zhou LM,Yuan LL,et al.NPM1 Is a Prognostic biomarker involved in immune infiltration of lung adenocarcinoma and associated with m6a modification and glycolysis[J].Front Immunol,2021,12:724741.
16 Ma L,Xue X,Zhang X,et al.The essential roles of m(6)A RNA modification to stimulate ENO1-dependent glycolysis and tumorigenesis in lung adenocarcinoma[J].J Exp Clin Cancer Res,2022,41(1):36.
17 Xue L,Li J,Lin Y,et al.m6 A transferase METTL3-induced lncRNA ABHD11-AS1 promotes the Warburg effect of non-small-cell lung cancer[J].J Cell Physiol,2021,236(4):2649-2658.
18 Xu P,Hu K,Zhang P,et al.Hypoxia-mediated YTHDF2 overexpression promotes lung squamous cell carcinoma progression by activation of the mTOR/AKT axis[J].Cancer Cell Int,2022,22(1):13.
19 Wang N,Xu Y,Jin L,et al.Effects of N6-Methyladenosine Regulators on LAG3 and immune infiltrates in lung adenocarcinoma[J].Dis Markers,2022,2022:1829528.
20 Hu K,Yao L,Yan Y,et al.Comprehensive analysis of YTH domain family in lung adenocarcinoma:expression profile,association with prognostic value,and immune infiltration[J].Dis Markers,2021,2021:2789481.
21 Wu L,Cheng D,Yang X,et al.M2-TAMs promote immunoresistance in lung adenocarcinoma by enhancing METTL3-mediated m6A methylation[J].Ann Transl Med,2022,10(24):1380.
22 Shi CY,Yu CH,Yu WY,et al.Gut-Lung microbiota in chronic pulmonary diseases:evolution,pathogenesis,and therapeutics[J].Can J Infect Dis Med Microbiol,2021,2021:9278441.
23 Li Y,Gu J,Xu F,et al.Molecular characterization,biological function,tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma[J].Brief Bioinform,2021,22(4):225.
24 Guo W,Huai Q,Zhang G,et al.Elevated heterogeneous nuclear ribonucleoprotein C expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma[J].Front Oncol,2020,10:598437.
25 Guo W,Huai Q,Wan H,et al.Prognostic impact of IGF2BP3 expression in patients with surgically resected lung adenocarcinoma[J].DNA Cell Biol,2021,40(2):316-331.
26 Xiao H,Zhao R,Meng W,et al.Effects and translatomics characteristics of a small-molecule inhibitor of METTL3 against non-small cell lung cancer[J].J Pharm Anal,2023,13(6):625-639.
27 Chen B,Ye F,Yu L,et al.Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor[J].J Am Chem Soc,2012,134(43):17963-17971.
28 Huang Y,Yan J,Li Q,et al.Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5[J].Nucleic Acids Res,2015,43(1):373-384.
29 Chen WW,Qi JW,Hang Y,et al.Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA[J].Eur Rev Med Pharmacol Sci,2020,24(8):4263-4270.
30 Choe J,Lin S,Zhang W,et al.mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis[J].Nature,2018,561(7724):556-560.
31 Lin S,Liu Q,Lelyveld VS,et al.Mettl1/Wdr4-Mediated m7G tRNA Methylome is required for normal mrna translation and embryonic stem cell self-renewal and differentiation[J].Mol Cell,2018,71(2):244-255.
32 Balzeau J,Menezes MR,Cao S,et al.The LIN28/let-7 Pathway in Cancer[J].Front Genet,2017,8:31.
33 Ma J,Han H,Huang Y,et al.METTL1/WDR4-mediated m7G tRNA modifications and m7G codon usage promote mRNA translation and lung cancer progression[J].Mol Ther,2021,29(12):3422-3435.
34 Wang G,Zhao M,Li J,et al.m7G-Associated subtypes,tumor microenvironment,and validation of prognostic signature in lung adenocarcinoma[J].Front Genet,2022,13:954840.
35 Zhang C,Zhou D,Wang Z,et al.Risk model and immune signature of m7G-Related lncRNA based on lung adenocarcinoma[J].Front Genet,2022,13:907754.
36 Huang W,Qi CB,Lv SW,et al.Determination of DNA and RNA methylation in circulating tumor cells by mass spectrometry[J].Anal Chem,2016,88(2):1378-1384.
37 Li M,Tao Z,Zhao Y,et al.5-methylcytosine RNA methyltransferases and their potential roles in cancer[J].J Transl Med,2022,20(1):214.
38 Wang Y,Wei J,Feng L,et al.Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer[J].Mol Cancer,2023,22(1):81.
39 Chen Z,Qi M,Shen B,et al.Transfer RNA demethylase ALKBH3 promotes cancer progression via induction of tRNA-derived small RNAs[J].Nucleic Acids Res,2019,47(5):2533-2545.
40 Tasaki M,Shimada K,Kimura H,et al.ALKBH3,a human AlkB homologue,contributes to cell survival in human non-small-cell lung cancer[J].Br J Cancer,2011,104(4):700-706.

[1]	XU Xianhui, CHEN Yang, ZHU Yunfang, LI Mingsong, WEN Hongmei. Incidence and mortality of lung cancer in cancer registration areas of Yunnan province in 2020 and the trends from 2012 to 2020 [J]. Journal of Practical Oncology, 2024, 38(6): 367-371.
[2]	HAO Huiting, ZHAO Huijuan, XU Qiaohui. Expression and clinical significance of hypermethylated in cancer 1 in non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(5): 306-312.
[3]	XU Lingyan, LI Qianni, LI Jian, YAO Xuepei, LIU Meina. Analysis for the impact of the first hospitalization days on treatment quality in patients with non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(4): 221-226.
[4]	YAO Xuepei, BAI Shanqi, LIU Meina. Analysis of factors influencing treatment quality of non-small cell lung cancer based on causal diagram model [J]. Journal of Practical Oncology, 2024, 38(4): 227-234.
[5]	LI Jian, LI Qianni, XU Lingyan, YAO Xuepei, LIU Meina. Research on the causal effects of non-small cell lung cancer treatment process on in-hospital mortality based on double robust estimation method [J]. Journal of Practical Oncology, 2024, 38(4): 235-240.
[6]	MA Na, LIU Jie. Analysis of lung cancer incidence and mortality in Hedong district,Tianjin,from 2015 to 2020 [J]. Journal of Practical Oncology, 2024, 38(4): 241-245.
[7]	CHENG Yongming, DONG Huanhuan, XU Hui. Hsa-let-7b-5p inhibits proliferation,migration and invasion in non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(3): 157-167.
[8]	WANG Wenbo, BAI Haixin, ZHANG Tan, NIU Li. Propofol inhibits glycolysis and tumor progression in lung cancer through GLUT4 [J]. Journal of Practical Oncology, 2024, 38(2): 104-111.
[9]	BO Yun, HANG Wenlu, ZUO Shurun, Dong Yuan, LI Haiquan. Effects of long non-coding RNA OTUD6B-AS1 on proliferation,invasion and migration of lung adenocarcinoma A549 cells [J]. Journal of Practical Oncology, 2024, 38(1): 13-17.
[10]	ZHANG Xuan, LI Xin, ZHAO Kang. Relationship between serum inflammatory markers and prognosis of advanced non-small cell lung cancer patients treated with first-line immunosuppressants [J]. Journal of Practical Oncology, 2024, 38(1): 37-44.
[11]	MIAO Ling, ZHAO Zhihan, WANG Min. Levels and clinical significance of PA28γ and miR-7-5p in tumor tissues of patients with non-small cell lung cancer [J]. Journal of Practical Oncology, 2023, 37(4): 344-350.
[12]	CAO Yingyue, PANG Luyi, ZHANG Jian, JIN Shi. The role of cancer-associated fibroblasts in the progression of non-small cell lung cancer [J]. Journal of Practical Oncology, 2023, 37(4): 383-388.
[13]	WEI Hong, WANG Zhaoxi, WANG Yichun, ZHOU Xianli. Clinical application value of contrast-enhanced ultrasound combined with acoustic radiation pulse imaging in peripheral lung masses [J]. Journal of Practical Oncology, 2023, 37(3): 236-242.
[14]	CHEN Qi, HE Mingxv, JIA Keliang, MIAO Jianlong, HAN Liping. Research progress on the prognosis and treatment of non-small cell lung cancer with TP53-EGFR co-mutation [J]. Journal of Practical Oncology, 2023, 37(3): 262-266.
[15]	LONG Chaolian, LI Kun, LIU Zichen, ZHANG Nana, CHE Nanying. The correlation between the expression of programmed death ligand 1 in non-small cell lung cancer and clinical pathological features and common driver gene mutation [J]. Journal of Practical Oncology, 2023, 37(2): 117-122.

Research progress of RNA methylation in lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments